| 前收市價 | 3.270 |
| 開市 | 3.270 |
| 買盤 | 3.330 x 0 |
| 賣出價 | 3.340 x 0 |
| 今日波幅 | 3.250 - 3.350 |
| 52 週波幅 | 2.590 - 5.820 |
| 成交量 | |
| 平均成交量 | 43,572,994 |
| 市值 | 53.746B |
| Beta 值 (5 年，每月) | 1.03 |
| 市盈率 (最近 12 個月) | 47.71 |
| 每股盈利 (最近 12 個月) | 0.070 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 5.58 |
- AASTOCKS
阿里健康(00241.HK)與九州通合作藥單數字化轉型
阿里健康(00241.HK)與九州通(600998.SH)宣布達成戰略合作協議，雙方將深化合作關係。合作的核心是利用「碼上放心」追溯服務平台，以推動電子藥檢報告單在醫藥流通鏈路中的應用，並加速藥品流通環節中紙質單據的數字化轉型。(ta/w)~ 阿思達克財經新聞 網址: www.aastocks.com
- InvestorPlace
Alibaba’s Risky Gamble: Can the E-Commerce Titan Bounce Back from Its Missteps?
Alibaba (NYSE:BABA) is an example of a stock that took its eye off the ball and struck out big. Now it is scrambling to regain its footing. Alibaba’s ongoing restructuring has failed to win over the market, resulting in a 9% year-to-date decline in its stock, a 22% decline over the last 12 months, and a more than 31% drop from its 52-week high. Although founder Jack Ma endorsed the Chinese online retailer’s turnaround plans, investors might not want to rush in. Alibaba is a behemoth. Righting th
